Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GALK1 | P51570 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | PLEC | Q15149 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 5/20 | 0.46 |
| ▸ | PYGM | P11217 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29406842 | 0.90 | POLB (0.73) | POLBHPSEALDH1A1L3MBTL1APEX1 | |
| SCHEMBL30553345 | 0.90 | POLB (0.73) | POLBHPSEALDH1A1L3MBTL1APEX1 | |
| SCHEMBL262311 | 0.90 | POLB (0.73) | POLBHPSEALDH1A1L3MBTL1APEX1 | |
| SCHEMBL145176 | 0.90 | POLB (0.73) | POLBHPSEALDH1A1L3MBTL1APEX1 | |
| SCHEMBL30901880 | 0.90 | POLB (0.73) | POLBHPSEALDH1A1L3MBTL1APEX1 | |
| SCHEMBL29426403 | 0.88 | POLB (0.70) | POLBHPSEALDH1A1L3MBTL1APEX1 | |
| SCHEMBL49365 | 0.88 | POLB (0.70) | POLBHPSEALDH1A1L3MBTL1APEX1 | |
| SCHEMBL29364655 | 0.88 | POLB (0.70) | POLBHPSEALDH1A1L3MBTL1APEX1 | |
| SCHEMBL21274783 | 0.87 | MAOB (0.51) | POLBHPSEXDHL3MBTL1APEX1 | |
| Water SCHEMBL6407539 | 0.86 | POLB (0.68) | POLBHPSEALDH1A1L3MBTL1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210060000-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2021-03-04 | — | — | US | disclosed |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2019-08-08 | — | — | US | disclosed |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9339527-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-8916585-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140343094-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2014-11-20 | — | — | US | disclosed |
| US-8765956-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-1436267-B1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-20060287321-A1 | Novel Lactam Derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-21 | — | — | US | disclosed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | disclosed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050059651-A1 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-03-17 | — | — | US | disclosed |
| CN-1596247-A | Lactam derivatives as antagonists of the human 11CBY receptor | SMITHKLINE BEECHAM PLC (GB) | 2005-03-16 | — | — | CN | disclosed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | disclosed |
| EP-1436267-A1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003033480-A1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | POLB 2962/4885HPSE 593/4885ALDH1A1 1476/4885 |
| US-20140343094-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | POLB 2931/4885HPSE 525/4885ALDH1A1 1908/4885 |
| US-20050059651-A1 | Lactam derivatives as antagonists for human 11cby receptors | ADRB3, GPR3, ADRB1 | POLB 3020/4885HPSE 4190/4885ALDH1A1 2468/4885 |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | POLB 2931/4885HPSE 525/4885ALDH1A1 1908/4885 |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | POLB 2962/4885HPSE 593/4885ALDH1A1 1476/4885 |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | POLB 2931/4885HPSE 525/4885ALDH1A1 1908/4885 |
| US-20060287321-A1 | Novel Lactam Derivatives | MRPL21, PEPD, STS | POLB 3169/4885HPSE 3244/4885ALDH1A1 2328/4885 |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | POLB 2962/4885HPSE 593/4885ALDH1A1 1476/4885 |
| US-20210060000-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN2, HIF1A | POLB 2677/4885HPSE 605/4885ALDH1A1 1674/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | POLB 3959/4885HPSE 271/4885ALDH1A1 1829/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | POLB 4028/4885HPSE 156/4885ALDH1A1 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.